Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bimosiamose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP known ✓ | P16109 | 2/20 | 1.00 |
| ▸ | SELPLG | Q14242 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bimosiamose SCHEMBL26341832 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| SCHEMBL7620761 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL14970212 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL14015902 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL2529148 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL12182030 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| SCHEMBL7614341 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL29367817 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL2528669 | 0.99 | SELP (0.98) | SELPSELPLGPPARGPPARDPPARA | |
| SCHEMBL8205205 | 0.99 | SELP (0.98) | SELPSELPLGPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024191702-A2 | P-SELECTIN INHIBITION TO TREAT HUMAN LYMPHEDEMA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-09-19 | — | — | WO | claimed |
| US-12599664-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-12594332-B2 | Methods of treating psoriasis with secukinumab | NOVARTIS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-12594331-B2 | Methods of treating psoriasis with secukinumab | NOVARTIS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-20260083842-A1 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | NOVARTIS AG (CH) | 2026-03-26 | — | — | US | disclosed |
| US-12551554-B2 | Methods of treating chronic inflammatory disease with secukinumab | NOVARTIS AG (CH) | 2026-02-17 | — | — | US | disclosed |
| US-12544438-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | NOVARTIS AG (CH) | 2026-02-10 | — | — | US | disclosed |
| US-12485172-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | NOVARTIS AG (CH) | 2025-12-02 | — | — | US | disclosed |
| US-12485173-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | NOVARTIS AG (CH) | 2025-12-02 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4008326-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | Pulmatrix Operating Company, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11351253-B2 | Methods of treating palmoplantar pustular psoriasis (PPP) using IL-17 antibody | NOVARTIS AG (CH) | 2022-06-07 | — | — | US | disclosed |
| WO-2022059008-A9 | METHODS OF TREATING GLIOBLASTOMA | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-06-02 | — | — | WO | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| WO-2022059008-A1 | METHODS OF TREATING GLIOBLASTOMA | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-03-24 | — | — | WO | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-11235112-B2 | Inhalable dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083842-A1 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | IL17A, RAB7A, IL15 | SELP 494/4885SELPLG 911/4885PPARG 2848/4885 |
| US-12551554-B2 | Methods of treating chronic inflammatory disease with secukinumab | IL17A, IL15, IL23R | SELP 52/4885SELPLG 46/4885PPARG 857/4885 |
| US-12544438-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | IL17A, IL15, STK17A | SELP 723/4885SELPLG 1300/4885PPARG 1629/4885 |
| US-12599664-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | IL17A, IL15, IL5 | SELP 428/4885SELPLG 794/4885PPARG 1067/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | SELP 4320/4885SELPLG 4241/4885PPARG 3594/4885 |
| US-12594332-B2 | Methods of treating psoriasis with secukinumab | IL17A, IL15, IL23R | SELP 31/4885SELPLG 24/4885PPARG 902/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | SELP 1727/4885SELPLG 1272/4885PPARG 1158/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | SELP 2958/4885SELPLG 2629/4885PPARG 1606/4885 |
| US-12594331-B2 | Methods of treating psoriasis with secukinumab | IL17A, IL15, IL15RA | SELP 41/4885SELPLG 30/4885PPARG 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.